Researchers published a large community-based study in Nature Communications demonstrating blood biomarkers correlate with cognitive stage and can track Alzheimer’s disease progression outside specialized centers. The team identified measurable plasma markers that rise and fall with cognitive decline, offering a scalable alternative to CSF and PET biomarkers. The work supports broader, less-invasive screening approaches and could accelerate trial enrollment and disease monitoring.